Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

被引：22
|
作者：
Wethington, Stephanie L.
Shah, Payal D.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Morgan, Mark Aloysuis
Torigian, Drew A.
Pagan, Cheyenne
Rodriguez, Diego
Domchek, Susan M.
Drapkin, Ronny
Shih, Le-Ming
Smith, Simon
Dean, Emma
Armstrong, Deborah Kay
Gaillard, Stephanie
Simpkins, Fiona
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Hosp Univ Penn, Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA
[6] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] AstraZeneca, Cambridge, England
[9] Univ Manchester, Manchester, Lancs, England
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[12] Johns Hopkins Sch Med, Baltimore, MD USA
[13] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5516
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
    Kristeleit, R. S.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2022, 33 (10) : 989 - 991
  • [42] EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.
    Westin, Shannon Neville
    Coleman, Robert L.
    Fellman, Bryan M.
    Yuan, Ying
    Sood, Anil K.
    Soliman, Pamela T.
    Wright, Alexi A.
    Horowitz, Neil S.
    Campos, Susana M.
    Konstantinopoulos, Panagiotis A.
    Levenback, Charles F.
    Gershenson, David Marc
    Lu, Karen H.
    Bayer, Virginia
    Tukdi, Sobiya
    Rabbit, Alexis
    Ottesen, Lone
    Godin, Robert
    Mills, Gordon B.
    Liu, Joyce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.
    Mirza, Mansoor Raza
    Feng, Bin
    Shan, Ming
    Sun, Kaiming
    Yalcin, Ilkar
    Coleman, Kevin
    Thress, Kenneth S.
    Hazard, Sebastien
    Wang, Jing Y.
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons
    Majithiya, Jayesh Bhanabhai
    Luzarraga, Marina Roy
    Newman, Richard
    Costales, Paula
    Jones, Philip
    Di Francesco, Maria Emilia
    Giuliani, Virginia
    Caroll, Chris
    Do, Mary Geck
    Heffernan, Tim
    Feng, Ningpeng
    Ma, XiaoYan
    Lively, Sarah
    Johnson, Michael G.
    Geo, Lerin
    Piscitello, Desiree
    Rajendra, Eeson
    Grinkevich, Vera
    Ranzani, Marco
    Stockley, Martin
    Langford, Gillian
    Heald, Robert
    Robinson, Helen M.
    Smith, Graeme C.
    CANCER RESEARCH, 2023, 83 (07)
  • [45] RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors
    Roulston, Anne
    Zimmerman, Michal
    Papp, Robert
    Skeldon, Alex
    Pellerin, Charles
    Dumas-Berube, Emilie
    Dumais, Valerie
    Dorich, Stephane
    Fournier, Sara
    Li, Li
    Leclaire, Marie-Eve
    Yin, Shou Yun
    Chefson, Amandine
    Alam, Hunain
    Yang, William
    Fugere-Desjardins, Chloe
    Hammond, Sabrina
    Skorey, Kathryn
    Mulani, Amina
    Rimkunas, Victoria
    Veloso, Artur
    Hamel, Martine
    Stocco, Rino
    Mamane, Yael
    Li, Zuomei
    Young, Jordan
    Zinda, Mike
    Black, Cameron
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [46] A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer
    Liu, J.
    Fleming, G. F.
    Tolaney, S. M.
    Birrer, M. J.
    Penson, R. T.
    Berlin, S. T.
    Whalen, C.
    Tyburski, K.
    Matijevich, K.
    Kasparian, E.
    Roche, M.
    Lee, H.
    Winer, E. P.
    Ivy, S. P.
    Matulonis, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Targeting Protein Phosphatase 2A in Combination with PARP inhibitors for the treatment of high-grade serous epithelial ovarian cancer.
    Avelar, Rita A.
    Armstrong, Amy
    Narla, Goutham
    DiFeo, Analisa
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 55 - 56
  • [48] KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors
    Cadzow, L.
    Gokhale, P. C.
    Ganapathy, S.
    Sullivan, P.
    Nayak, S.
    Shenker, S.
    Schlabach, M.
    Tobin, E.
    Matulonis, U. A.
    Liu, J. F.
    Stegmeier, F.
    Wylie, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S37 - S38
  • [49] Combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models
    Hao, Jie
    Bose, Arindam
    Sadatrezaei, Golbahar
    Martignetti, David B.
    Jiao, Yuqing
    da Costa, Alexandre Andre B.
    Lazaro, Jean-Bernard
    Kochupurakkal, Bose
    Huy Nguyen
    Parmar, Kalindi
    D'Andrea, Alan D.
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2023, 83 (07)
  • [50] Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
    Do, Khanh T.
    Kochupurakkal, Bose
    Kelland, Sarah
    de Jonge, Adrienne
    Hedglin, Jennifer
    Powers, Allison
    Quinn, Nicholas
    Gannon, Courtney
    Vuong, Loan
    Parmar, Kalindi
    Lazaro, Jean-Bernard
    D'Andrea, Alan D.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4710 - 4716
12345